Abstract
Attempts have been made by conventional gene therapy to suppress hepatic fibrogenesis, but potential oncogenic activity may prevent its clinical use. Recently, a novel major approach has been developed for resolution of liver fibrosis and cirrhosis: inactivation of hepatic stellate cells (HSC) using the endogenous expressing gene, which could mediate the homeostatic adaptation of liver. Cytoglobin (Cygb), originally identified in cultured rat HSC, is in a new class of heme containing proteins known as the hexacoordinate globin superfamily. These proteins exhibit peroxidase activity against hydrogen peroxides and lipid hydroperoxides. Considerable attention has been focused on the potential benefits of use of Cygb in fibrosis therapy, as up-regulation of Cygb expression could reduce oxidant stress, suppress HSC differentiation to a myofibroblast-like phenotype and eventually prevent the progress of liver fibrosis. Cygb has also been found to be a candidate tumor suppressor gene that might provide a new option for cancer gene therapy. In this review we systematically analyze the potential of Cygb as a prospective gene medicine for curing fibrosis, cancer, and other diseases such as diabetes. The molecular structure, regulation and subcellular location of Cygb are reviewed as well.
Keywords: Hexacoordination, oxidative stress, hypoxia, up-regulation, stellate cell, tumor suppressor, hypermethylated, gene therapy
Current Gene Therapy
Title: Cytoglobin:A Novel Potential Gene Medicine for Fibrosis and Cancer Therapy
Volume: 8 Issue: 4
Author(s): Yinghui Lv, Qizhao Wang, Yong Diao and Ruian Xu
Affiliation:
Keywords: Hexacoordination, oxidative stress, hypoxia, up-regulation, stellate cell, tumor suppressor, hypermethylated, gene therapy
Abstract: Attempts have been made by conventional gene therapy to suppress hepatic fibrogenesis, but potential oncogenic activity may prevent its clinical use. Recently, a novel major approach has been developed for resolution of liver fibrosis and cirrhosis: inactivation of hepatic stellate cells (HSC) using the endogenous expressing gene, which could mediate the homeostatic adaptation of liver. Cytoglobin (Cygb), originally identified in cultured rat HSC, is in a new class of heme containing proteins known as the hexacoordinate globin superfamily. These proteins exhibit peroxidase activity against hydrogen peroxides and lipid hydroperoxides. Considerable attention has been focused on the potential benefits of use of Cygb in fibrosis therapy, as up-regulation of Cygb expression could reduce oxidant stress, suppress HSC differentiation to a myofibroblast-like phenotype and eventually prevent the progress of liver fibrosis. Cygb has also been found to be a candidate tumor suppressor gene that might provide a new option for cancer gene therapy. In this review we systematically analyze the potential of Cygb as a prospective gene medicine for curing fibrosis, cancer, and other diseases such as diabetes. The molecular structure, regulation and subcellular location of Cygb are reviewed as well.
Export Options
About this article
Cite this article as:
Lv Yinghui, Wang Qizhao, Diao Yong and Xu Ruian, Cytoglobin:A Novel Potential Gene Medicine for Fibrosis and Cancer Therapy, Current Gene Therapy 2008; 8 (4) . https://dx.doi.org/10.2174/156652308785160656
DOI https://dx.doi.org/10.2174/156652308785160656 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets
Current Medicinal Chemistry Synthesis, Cytotoxicity and Antioxidant Activity of New Analogs of RC-121 Synthetic Derivatives of Somatostatin
Anti-Cancer Agents in Medicinal Chemistry Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry Radionuclide Molecular Imaging Using Affibody Molecules
Current Pharmaceutical Biotechnology The Role of Maternal Serum Biomarkers in the Early Diagnosis of Ectopic Pregnancy
Current Chemical Biology Recent Advances on 3-Hydroxyflavone Derivatives: Structures and Properties
Mini-Reviews in Medicinal Chemistry Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Dual Inhibitors of β-Amyloid Aggregation and Acetylcholinesterase as Multi-Target Anti-Alzheimer Drug Candidates
Current Topics in Medicinal Chemistry Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
Current Medicinal Chemistry New Procaspase Activating Compound (PAC-1) Like Molecules as Potent Antitumoral Agents Against Lung Cancer
Letters in Drug Design & Discovery Development of Taxol and Other Endophyte Produced Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies
Anti-Cancer Agents in Medicinal Chemistry Chemoprevention of Breast Cancer by Dietary Compounds
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics/Pharmacodynamics Model-Supported Early Drug Development
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Current Cancer Drug Targets Recent Patents on Radiotherapy Bed
Recent Patents on Mechanical Engineering Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Structure-Guided Design of Antibodies
Current Computer-Aided Drug Design